Romidepsin for the treatment of T-cell lymphomas

American Journal of Health-System Pharmacy

Volumn 70, Issue 13, 2013, Pages 1115-1122

  McGraw, Angie L ^a  

^a Middle Tennessee Medical Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 3A; ROMIDEPSIN; ANTINEOPLASTIC ANTIBIOTIC; DEPSIPEPTIDE;

AREA UNDER THE CURVE; CANCER CHEMOTHERAPY; CUTANEOUS T CELL LYMPHOMA; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; FATIGUE; HUMAN; MAXIMUM PLASMA CONCENTRATION; NAUSEA; NEUTROPENIA; PERIPHERAL T CELL LYMPHOMA; PHASE 2 CLINICAL TRIAL (TOPIC); REVIEW; THROMBOCYTOPENIA; TREATMENT RESPONSE; VOMITING; CHEMICALLY INDUCED; DRUG EFFECTS; DRUG RESISTANCE; LYMPHOMA, T-CELL; REMISSION; TREATMENT OUTCOME;

ANTIBIOTICS, ANTINEOPLASTIC; CLINICAL TRIALS, PHASE II AS TOPIC; DEPSIPEPTIDES; DRUG RESISTANCE, NEOPLASM; FATIGUE; HUMANS; LYMPHOMA, T-CELL; NAUSEA; REMISSION INDUCTION; TREATMENT OUTCOME; VOMITING;

EID: 84891444921     PISSN: 10792082     EISSN: 15352900     Source Type: Journal    
DOI: 10.2146/ajhp120163     Document Type: Review

References (77)

1. Lansigan F, Choi J, Foss FM. Cutaneous T-cell lymphoma. Hematol Oncol Clin North Am. 2008; 22:979-96.
2. Cutaneous Lymphoma Foundation. CTCL-MF fast facts. http://clfoundation.org/publications/CL-fast-facts.pdf (accessed 2011 Jul 19).
3. Olsen E, Vonderheid E, Pimpinelli N et al. Revisions to the staging and classification of mycosis fungoides and Sezary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of Cancer (EORTC). Blood. 2007; 110:1713-22.
4. Kim YH, Liu HL, Mraz-Gernhard S et al. Long-term outcome of 525 patients with mycosis fungoides and Sezary syndrome: clinical prognostic factors and risk for disease progression. Arch Dermatol. 2003; 139:857-66.
5. Scarisbrick JJ, Whittaker S, Evans AV et al. Prognostic significance of tumor burden in the blood of patients with erythrodermic primary cutaneous T-cell lymphoma. Blood. 2001; 97:624-30.
6. Whittaker SJ, Foss FM. Efficacy and tolerability of currently available therapies for the mycosis fungoides and Sezary syndrome variants of cutaneous T-cell lymphoma. Cancer Treat Rev. 2007; 33:146-60.
7. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: non-Hodgkin's lymphoma, v.I.2013. www.nccn.org/professionals/physician-gls/pdf/nhl.pdf (accessed 2013 May 1).
8. Dearden CE, Foss FM. Peripheral T-cell lymphomas: diagnosis and management. Hematol Oncol Clin North Am. 2003; 17:1351-66.
9. Horwitz SM. Management of peripheral T-cell non-Hodgkin's lymphoma. Curr Opin Oncol. 2007; 19:438-43.
10. Lopez-Guillermo A, Cid J, Salar A et al. Peripheral T-cell lymphomas: initial features, natural history, and prognostic factors in a series of 174 patients diagnosed according to the R.E.A.L. classification. Ann Oncol. 1998; 9:849-55.
11. Harris NJ, Jaffe ES, Armitage JO. Lymphoma classification: from REAL to WHO and beyond. In: DeVita VT, Hellman S, Rosenberg SA, eds. Cancer: principles and practice of oncology updates. Vol 13. Philadelphia: Lippincott-Raven; 1999:1-14.
12. Ascani S, Zinzani PL, Gherlinzoni F et al. Peripheral T-cell lymphomas. Clinicopathologic study of 168 cases diagnosed according to the R.E.A.L. classification. Ann Oncol. 1997; 8:583-92.
13. Anderson JR, Armitage JO, Weisenburger DD, for the Non-Hodgkin's Lymphoma Classification Project. Epidemiology of the non-Hodgkin's lymphomas: distributions of the major subtypes differ by geographic locations. Ann Oncol. 1998; 9:717-20.
14. Nakamura S, Koshikawa T, Koike K et al. Phenotypic analysis of peripheral T cell lymphoma among the Japanese. Acta Pathol Jpn. 1993; 43:396-412.
15. Vose J, Armitage J, Weisenburger D, for the International T-Cell Lymphoma Project. International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes. J Clin Oncol. 2008; 26:4124-30.
16. A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. N Engl J Med. 1993; 329:987-94.
17. Reimer P. Impact of autologous and allogeneic stem cell transplantation in peripheral T-cell lymphomas. Adv Hematol. 2010; 2010:320624.
18. Bradner JE, West N, Grachan ML et al. Chemical phylogenetics of histone deacetylases. Nat Chem Biol. 2010; 6:238-43.
19. Nakajima H, Kim YB, Terano H et al. FR901228, a potent antitumor antibiotic, is a novel histone deacetylase inhibitor. Exp Cell Res. 1998; 241:126-33.
20. Istodax (romidepsin) package insert. Summit, NJ: Celgene Corporation; 2011 Sep.
21. Folotyn (pralatrexate) package insert. Westminster, CO: Allos Therapeutics, Inc.; 2011 Jan.
22. Ueda H, Nakajima H, Hori Y et al. FR901228, a novel antitumor bicyclic depsipeptide produced by Chromobacterium violaceum no. 968. I. Taxonomy, fermentation, isolation, physico-chemical and biological properties, and antitumor activity. J Antibiot (Tokyo). 1994; 47:301-10.
23. Bolden JE, Peart MJ, Johnstone RW. Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov. 2006; 5:769-84.
24. Ho E, Clarke JD, Dashwood RH. Dietary sulforaphane, a histone deacetylase inhibitor for cancer prevention. J Nutr. 2009; 139:2393-6.
25. Brandl A, Heinzel T, Kramer OH. Histone deacetylases: salesmen and customers in the post-translational modification market. Biol Cell. 2009; 101:193-205.
26. Vigushin DM, Coombes RC. Histone deacetylase inhibitors in cancer treatment. Anticancer Drugs. 2002; 13:1-13.
27. Juan LJ, Shia WJ, Chen MH et al. Histone deacetylases specifically down-regulate p53-dependent gene activation. J Biol Chem. 2000; 275:20436-43.
28. Rasheed W, Bishton M, Johnstone RW et al. Histone deacetylase inhibitors in lymphoma and solid malignancies. Expert Rev Anticancer Ther. 2008; 8:413-32.
29. Cress WD, Seto E. Histone deacetylases, transcriptional control, and cancer. J Cell Physiol. 2000; 184:1-16.
30. Santini V, Gozzini A, Ferrari G. Histone deacetylase inhibitors: molecular and biological activity as a premise to clinical application. Curr Drug Metab. 2007; 8:383-93.
31. Emanuele S, Lauricella M, Tesoriere G. Histone deacetylase inhibitors: apoptotic effects and clinical implications (review). Int J Oncol. 2008; 33:637-46.
32. Tan J, Cang S, Ma Y et al. Novel histone deacetylase inhibitors in clinical trials as anti-cancer agents. J Hematol Oncol. 2010; 3:5.
33. Furumai R, Matsuyama A, Kobashi N et al. FK228 (depsipeptide) as a natural prodrug that inhibits class I histone deacetylases. Cancer Res. 2002; 62:4916-21.
34. Minucci S, Pelicci PG. Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nat Rev Cancer. 2006; 6:38-51.
35. Witt O, Deubzer HE, Milde T et al. HDAC family: what are the cancer relevant targets? Cancer Lett. 2009; 277:8-21.
36. Peart MJ, Smyth GK, van Laar RK et al. Identification and functional significance of genes regulated by structurally different histone deacetylase inhibitors. Proc Natl Acad Sci U S A. 2005; 102:3697-702.
37. Newbold A, Lindemann RK, Cluse LA et al. Characterization of the novel apoptotic and therapeutic activities of the histone deacetylase inhibitor romidepsin. Mol Cancer Ther. 2008; 7:1066-79.
38. Lindemann RK, Newbold A, Whitecross KF et al. Analysis of the apoptotic and therapeutic activities of histone deacetylase inhibitors by using a mouse model of B cell lymphoma. Proc Natl Acad Sci U S A. 2007; 104:8071-6.
39. Shao W, Growney JD, Feng Y et al. Activity of deacetylase inhibitor panobinostat (LBH589) in cutaneous T-cell lymphoma models: defining molecular mechanisms of resistance. Int J Cancer. 2010; 127:2199-208.
40. Piekarz RL, Frye R, Prince HM et al. Phase 2 trial of romidepsin in patients with peripheral T-cell lymphoma. Blood. 2011; 117:5827-34.
41. Piekarz RL, Frye R, Turner M et al. Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma. J Clin Oncol. 2009; 27:5410-7.
42. Woo S, Gardner ER, Chen X et al. Population pharmacokinetics of romidepsin in patients with cutaneous T-cell lymphoma and relapsed peripheral T-cell lymphoma. Clin Cancer Res. 2009; 15:1496-503.
43. Fouladi M, Furman WL, Chin T et al., for the Children's Oncology Group. Phase I study of depsipeptide in pediatric patients with refractory solid tumors: a Children's Oncology Group report. J Clin Oncol. 2006; 24:3678-85.
44. Byrd JC, Marcucci G, Parthun MR et al. A phase 1 and pharmacodynamic study of depsipeptide (FK228) in chronic lymphocytic leukemia and acute myeloid leukemia. Blood. 2005; 105:959-67.
45. Bates SE, Zhan Z, Steadman K et al. Laboratory correlates for a phase II trial of romidepsin in cutaneous and peripheral T-cell lymphoma. Br J Haematol. 2010; 148:256-67.
46. Piekarz RL, Robey R, Sandor V et al. Inhibitor of histone deacetylation, depsipeptide (FR901228), in the treatment of peripheral and cutaneous T-cell lymphoma: a case report. Blood. 2001; 98:2865-8.
47. Sandor V, Bakke S, Robey RW et al. Phase I trial of the histone deacetylase inhibitor, depsipeptide (FR901228, NSC 630176), in patients with refractory neoplasms. Clin Cancer Res. 2002; 8:18-728.
48. Marshall JL, Rizvi N, Kauh J et al. A phase I trial of depsipeptide (FR901228) in patients with advanced cancer. J Exp Ther Oncol. 2002; 2:325-32.
49. Whittaker S, Demierre M, Kim EJ et al. Final results from a multicenter, international, pivotal study of romidepsin in refractory cutaneous T-cell lymphoma. J Clin Oncol. 2010; 28:4485-91.
50. Whittaker S, Frye R, Nichols J et al. Complete responses with romidepsin in cutaneous T-cell lymphoma (CTCL) studies. Poster presented at the World Congress of Cutaneous Lymphomas. Chicago, IL; 2010 Sep 22.
51. Kim EJ, Kim YH, Rook AH et al. Clinically significant responses achieved with romidepsin across disease compartments in patients with cutaneous T-cell lymphoma (CTCL). Poster presented at the World Congress of Cutaneous Lymphomas. Chicago, IL; 2010 Sep 22.
52. Kim YH, Demierre M, Lerner A et al. Clinically relevant pruritus reduction in cutaneous T-cell lymphoma (CTCL) patients treated with romidepsin. Poster presented at the World Congress of Cutaneous Lymphomas. Chicago, IL; 2010 Sep 22.
53. Coiffier B, Pro B, Prince M et al. Romidepsin induces durable responses in patients with peripheral T-cell lymphoma: GPI-06-0002 study update. Blood. 2012; 120:3641. Abstract.
54. Whittaker S, Prince M, Demierre MF et al. Characterization of cyclic hematologic changes observed in patients with cutaneous T-cell lymphoma (CTCL) receiving romidepsin, a novel histone deacetylase (HDAC) inhibitor. Blood. 2009; 114:3701. Abstract.
55. Molife R, Fong P, Scurr M et al. HDAC inhibitors and cardiac safety. Clin Cancer Res. 2007; 13:1068 [author reply, 1068-9].
56. Shah MH, Binkley P, Chan K et al. Cardiotoxicity of histone deacetylase inhibitor depsipeptide in patients with metastatic neuroendocrine tumors. Clin Cancer Res. 2006; 12:3997-4003.
57. Cabell C, Bates S, Piekarz R et al. Systematic assessment of potential cardiac effects of the novel histone deacetylase (HDAC) inhibitor romidepsin. Blood. 2009; 114:3709. Abstract.
58. Godfrey CJ, Cabell CH, Balser B et al. Exposure-QTc response analysis of class 1 selective histone deacetylase inhibitor romidepsin. Blood. 2011; 118:2680. Abstract.
59. Piekarz RL, Frye AR, Wright JJ et al. Cardiac studies in patients treated with depsipeptide, FK228, in a phase II trial for T-cell lymphoma. Clin Cancer Res. 2006; 12:3762-73.
60. Dupuis J, Casanovas R-O, Ghesquieres H et al. A phase Ib trial of romidepsin in association with CHOP in patients with peripheral T-cell lymphoma (PTCL): the R0-CHOP Study. Blood. 2012; 120:1617. Abstract.
61. Whitehead RP, Rankin C, Hoff PM et al. Phase II trial of romidepsin (NSC-630176) in previously treated colorectal cancer patients with advanced disease: a Southwest Oncology Group study (S0336). Invest New Drugs. 2009; 27:469-75.
62. Molife LR, Attard G, Fong PC et al. Phase II, two-stage, single-arm trial of the histone deacetylase inhibitor (HDACi) romidepsin in metastatic castrationresistant prostate cancer (CRPC). Ann Oncol. 2010; 21:109-13.
63. Stadler WM, Margolin K, Ferber S et al. A phase II study of depsipeptide in refractory metastatic renal cell cancer. Clin Genitourin Cancer. 2006; 5:57-60.
64. Odenike OM, Alkan S, Sher D et al. Histone deacetylase inhibitor romidepsin has differential activity in core binding factor acute myeloid leukemia. Clin Cancer Res. 2008; 14:7095-101.
65. Piekarz R, Luchenko V, Draper D et al. Phase I trial of romidepsin, a histone deacetylase inhibitor, given on days one, three and five in patients with thyroid and other advanced cancers. J Clin Oncol. 2008; 26(suppl 20):3571. Abstract.
66. Schrump DS, Fischette MR, Nguyen DM et al. Clinical and molecular responses in lung cancer patients receiving romidepsin. Clin Cancer Res. 2008; 14:188-98.
67. Otterson GA, Hodgson L, Pang H et al., for the Cancer and Leukemia Group B. Phase II study of the histone deacetylase inhibitor romidepsin in relapsed small cell lung cancer (Cancer and Leukemia Group B 30304). J Thorac Oncol. 2010; 5:1644-8.
68. Niesvizky R, Ely S, Mark T et al. Phase 2 trial of the histone deacetylase inhibitor romidepsin for the treatment of refractory multiple myeloma. Cancer. 2010; 117:336-42.
69. Iwamoto FM, Lamborn KR, Kuhn JG et al. A phase I/II trial of the histone deacetylase inhibitor, romidepsin, for adults with recurrent malignant glioma: North American Brain Tumor Consortium study 03-03. Neuro Oncol. 2011; 13:509-16.
70. Harrison SJ, Quach H, Link E et al. A high rate of durable responses with romidepsin, bortezomib, and dexamethasone in relapsed or refractory multiple myeloma. Blood. 2011; 118:6274-83.
71. Jones SF, Infante JR, Spigel DR et al. Phase 1 results from a study of romidepsin in combination with gemcitabine in patients with advanced solid tumors. Cancer Invest. 2012; 30:481-6.
72. Marchi E, Bongero DC, Kalac M et al. The combination of histone deacetylase inhibitors and hypomethylating agents exhibits marked synergy in preclinical models of T-cell lymphoma. Blood. 2010; 116:3937. Abstract.
73. Deshpande SD, Lechoqicz MJ, Sinha R et al. The combination of romidepsin and bortezomib results in synergistic induction of apoptosis in human B-lymphoma cell lines. Blood. 2009; 114:1689. Abstract.
74. Harrison SJ, Quach H, Yuen K et al. High response rates with the combination of bortezomib, dexamethasone, and the pan-histone deacetylase inhibitor romidepsin in patients with relapsed or refractory multiple myeloma in a phase I/II clinical trial. Blood. 2008; 112:3698. Abstract.
75. Chai G, Li L, Zhou W et al. HDAC inhibitors act with 5-aza-2′-deoxycytidine to inhibit cell proliferation by suppressing removal of incorporated abases in lung cancer cells. PLoS One. 2008; 3:e2445. Abstract.
76. Zhang W, Peyton M, Xie Y et al. Histone deacetylase inhibitor romidepsin enhances anti-tumor effect of erlotinib in non-small cell lung cancer (NSCLC) cell lines. J Thorac Oncol. 2009; 4:161-6.
77. Nguyen DM, Schrump WD, Tsai WS et al. Enhancement of depsipeptide-mediated apoptosis of lung or esophageal cancer cells by flavopiridol: activation of the mitochondria-dependent death-signaling pathway. J Thorac Cardiovasc Surg. 2003; 125:1132-42.